CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands
2021 ANNUAL HIV TESTING REPORT

OVERVIEW

The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates data on CDC-funded HIV testing and prevention activities reported through the National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reporting system, EvaluationWeb®. These data are used to assess the impact of CDC-funded HIV testing efforts, inform programmatic activities, and document the progress of programs toward local, state, and national HIV prevention goals.

This report describes the demographics of persons tested, newly diagnosed with HIV, and linked to HIV medical care within 30 days in the United States, Puerto Rico, and U.S. Virgin Islands in 2021. Data presented in this report include HIV test-level data reported to CDC through EvaluationWeb® as of September 15, 2022 from 60 state and local health departments (HDs) and 150 community-based organizations (CBOs). It is important to note that many CDC-funded jurisdictions continued to experience interruptions in the provision and reporting of HIV testing and related services in 2021 due to the COVID-19 pandemic.

Figure Showing Total CDC funded HIV-tests

CDC-funded HIV testing by setting & site type*

A total of 1,736,850 CDC-funded HIV tests were conducted in 2021. Most tests were conducted in health care settings (74%) such as Sexually Transmitted Disease (STD) Clinics and Community Health Centers. The tables below show the number of tests conducted and the percentage of tests resulting in new diagnoses (newly diagnosed % positivity) by site type.

health care settings
non-health care settings

* Not shown: 16,743 tests were conducted in mobile settings, 3,990 self-tests were reported, and 1,539 tests were missing information on site type.
a Health care sites where medical services are provided other than those specified including primary care clinics, substance abuse treatment facilities, pharmacies, dental clinics, TB clinics, and inpatient hospitals.
b Includes schools/educational facilities, church/mosque/synagogue/temple, commercial facilities, bar/club/adult entertainment, public areas, and individual residences.
c Non-health care sites where prevention services are conducted other than those specified including health department field visits and syringe exchange programs.

Newly diagnosed HIV positivity by age, gender, race/ethnicity, and population group

Among the 1,736,850 CDC-funded HIV tests conducted, 8,149 (0.5%) persons were newly diagnosed with HIV. The figures below show newly diagnosed positivity (i.e., percentage of persons newly diagnosed with HIV among all CDC-funded tests conducted) by demographic characteristics and population groups. Additional information, including number of tests conducted by category, can be found in Appendix Table 4.

Chart-Showing-Newly-Diagnosed-by-Age
Chart-Showing-Newly-Diagnosed-by-Gender
Chart-showing-Newly-Diagnosed-by-Race-and-Ethnicity
Chart-showing-Newly-Diagnosed-by-Population-Group

a “<13 years” category is not shown.
b Transgender persons are defined as persons whose current gender identity differs from their sex assigned at birth. Persons with assigned sex at birth as “Male” and current gender identity as “Transgender – Female to Male”; assigned sex at birth as “Female” and current gender identity as “Transgender – Male to Female”; and records classified as “Unknown” are excluded.
c All races are non-Hispanic/Latino. Hispanic/Latino ethnicity can be of any race. “More than one race” category is not shown.
d Data on behaviors that define population groups are collected for all tests performed in non-health care settings and for HIV-positive persons in health care settings. Groups are mutually exclusive and based on behaviors in the past 12 months under the old (prior to 2018) NHM&E reporting requirements and in the past 5 years under the new NHM&E reporting requirements. MSM and PWID includes men who reported both male-to-male sexual contact and injection drug use. MSM includes men who reported male-to-male sexual contact. PWID includes persons who reported injection drug use.

CDC-funded HIV testing in 60 jurisdictions

Among 8,149 persons newly diagnosed with HIV, 78% were linked to HIV medical care within 30 days of their positive test and 75% were interviewed for partner services. The reported percentages varied by jurisdiction, as shown in Table 1.

Data presented in this report include HIV test-level data from 60 state and local health departments (HDs) and 150 community-based organizations (CBOs) directly funded by CDC through 5 funding opportunities (PS15-1502, PS17-1704, PS18-1802, PS20-2010, and PS21-2102) and reported to CDC through EvaluationWeb® as of September 15, 2022. HDs funded through PS18-1802 and PS20-2010 and CBOs funded through PS17-1704 transitioned to new NHM&E data reporting requirements (i.e., required set of variables and program indicators) in 2018-2019. CBOs directly funded through PS15-1502 did not transition to new reporting requirements. CBOs directly funded through PS21-2102 utilized the new data reporting requirements. Test-level data reported under the old (prior to 2018) and new requirements were analyzed separately and resulting counts were combined in the tables and figures displayed.

DEFINITIONS AND INTERPRETING THIS REPORT

  • An HIV test is defined as a sequence of one or more HIV tests conducted to determine a person’s HIV status.
  • Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
  • NHM&E data are collected at the test-level; therefore, data included in this report represent test records rather than individuals. Clients tested multiple times may be included in the data.
  • A person with newly diagnosed HIV is a person who tests positive on the current test and has no indication of a previous positive test (includes persons with unconfirmed preliminary positive rapid tests and persons with confirmed positive tests).
  • The reported percentage of persons linked to HIV medical care within 30 days is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates actual linkage. Similarly, the reported percentage of persons interviewed for partner services is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates the actual percentage interviewed.
  • Procedures for data collection and verification vary among jurisdictions. For example, some jurisdictions accept a client’s self-report as adequate evidence that the client is newly diagnosed or has been linked to HIV medical care; whereas others require a cross-check with the surveillance system to rule out prior diagnosis or to verify linkage to care.
  • Jurisdictions vary considerably in resources available for HIV prevention and in the contexts in which they operate, which can affect program capacity. For example, some jurisdictions may receive state and local funds in addition to federal funds, whereas others may not. Examples of contextual issues that may affect program capacity include HIV prevalence, geography, political environment, laws and regulations, program infrastructure, surveillance system capacity, and accessibility to surveillance data to help guide program activities.
  • Because the population accessing HIV testing services at publicly funded sites is not necessarily representative of all persons who are tested for HIV in the United States, these findings should not be applied to the general population.

Publication of this report would not have been possible without the hard work and dedication of state and local health departments and community-based organizations that collected and submitted the HIV test-level data. This report was prepared by Deesha Patel, Guoshen Wang, Arin Blake, and Carolyn Wright of the Translation and Evaluation Branch in the Division of HIV Prevention. We also acknowledge the contributions of Lisa Kimbrough and Yuko Mizuno of the Translation and Evaluation Branch; the Office of Informatics and Data Management; and the Program Development and Implementation Branch for their contribution toward monitoring and strengthening HIV prevention efforts in state and local health departments and community-based organizations.

Suggested citation: Centers for Disease Control and Prevention. CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021http://www.cdc.gov/hiv/library/reports/index.html. Published April 2023. Accessed [Date].

For more information, contact:
Division of HIV Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
U.S. Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30329
Phone: 1-800-CDC-INFO
Web address: http://www.cdc.gov/HIV

National HIV Prevention Program Monitoring and Evaluation Service Center
Phone: 1-855-374-7310, Email: NHMEservice@cdc.gov

TABLES

Table 1. CDC-funded HIV testing and outcomes among persons newly diagnosed with HIV in the United States, Puerto Rico, and U.S. Virgin Islands, 2021
HIV tests
CDC-funded jurisdiction Number of HIV tests conducted in 2021 Number (%) of persons newly diagnosed with HIV Percentage of persons newly diagnosed with HIV linked to HIV medical care within 30 days* Percentage of persons newly diagnosed with HIV interviewed for partner services*
Alabama 60,250 323 (0.5%) 72% 69%
Alaska 426 2 (0.5%) 100% 100%
Arizona 59,817 238 (0.4%) 86% 89%
Arkansas 22,091 24 (0.1%) 76% 87%
California
Los Angeles 54,816 389 (0.7%) 56% 26%
San Francisco 22,947 128 (0.6%) 45% 56%
California (excludes Los Angeles and San Francisco) 26,836 234 (0.9%) 85% 63%
Colorado 7,213 64 (0.9%) 81% 97%
Connecticut 77,201 109 (0.1%) 94% 98%
Delaware 4,754 15 (0.3%) 87% 87%
District of Columbia 15,104 114 (0.8%) 79% 36%
Florida 215,778 1,261 (0.6%) 77% 95%
Georgia 86,171  694 (0.8%) 79% 54%
Hawaii 1,717 10 (0.6%) 78% 100%
Idaho 6,047 11 (0.2%) 100% 100%
Illinois
Chicago 6,479 33 (0.5%) 77% 73%
Illinois (excludes Chicago) 38,423 23 (0.1%) 91% 100%
Indiana 16,635 80 (0.5%) 65% 64%
Iowa 8,128 29 (0.4%) 92% 83%
Kansas 14,382 40 (0.3%) 78% 95%
Kentucky 14,291 33 (0.2%) 43% 90%
Louisiana 91,510 245 (0.3%) 88% 100%
Maine 1,117 6 (0.5%) 50% 83%
Maryland
Baltimore 25,774 49 (0.2%) 73% 84%
Maryland (excludes Baltimore) 21,468 26 (0.1%) 75% 22%
Massachusetts 39,124 90 (0.2%) 76% 59%
Michigan 22,908 149 (0.7%) 78% 73%
Minnesota 3,558 10 (0.3%) 88% 33%
Mississippi 28,214 122 (0.4%) 63% 92%
Missouri 11,707 77 (0.7%) 44% 92%
Montana 1,565 0 (0.0%) N/A N/A
Nebraska 4,274 16 (0.4%) 69% 63%
Nevada 18,633 132 (0.7%) 93% 90%
New Hampshire 430 0 (0.0%) N/A N/A
New Jersey 33,046 234 (0.7%) 87% 73%
New Mexico 6,048 32 (0.5%) 72% 75%
New York
New York City 35,392 154 (0.4%) 84% 60%
New York (excludes New York City) 14,526 108 (0.7%) 84% 81%
North Carolina 23,427 70 (0.3%) 53% 79%
North Dakota 3,962 6 (0.2%) 50% 100%
Ohio 7,209 145 (2.0%) 78% 77%
Oklahoma 4,171 17 (0.4%) 100% N/A
Oregon 7,146 33 (0.5%) 50% 90%
Pennsylvania
Philadelphia 27,424 119 (0.4%) 84% 40%
Pennsylvania (excludes Philadelphia) 51,168 143 (0.3%) 81% 92%
Rhode Island 1,201 2 (0.2%) 50% 100%
South Carolina 60,124 274 (0.5%) 76% 65%
South Dakota 973 3 (0.3%) 67% 100%
Tennessee 63,275 499 (0.8%) 90% 96%
Texas
Houston 72,876 326 (0.4%) 84% 80%
Texas (excludes Houston) 227,018 841 (0.4%) 79% 52%
Utah 1,716 7 (0.4%) 43% 86%
Vermont 29 0 (0%) N/A N/A
Virginia 26,750 119 (0.4%) 82% 93%
Washington 10,080 40 (0.4%) 70% 72%
West Virginia 3,488 6 (0.2%) 100% 100%
Wisconsin 8,429 29 (0.3%) 79% 71%
Wyoming 3,033 1 (0.0%) 0% 100%
Puerto Rico 13,293 150 (1.1%) 87% 88%
U.S. Virgin Islands 1,258 15 (1.2%) 50% 77%
Total 1,736,850 8,149 (0.5%) 78% 75%

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
N/A= Not Applicable
* Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or “Don’t Know”).

Appendix Table 1. Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
HIV-positive testsb
HIV testsa Newly diagnosed HIV-positive testsc Previously diagnosed HIV-positive testsd Unable to determine prior HIV statuse Total
CDC-funded jurisdiction No. No. (%) No. (%) No. (%) No. (%)
Alabama 60,250 323 (0.5) 397 (0.7) 76 (0.1) 796 (1.3)
Alaska 426 2 (0.5) 1 (0.2) 0 (0.0) 3 (0.7)
Arizona 59,817 238 (0.4) 146 (0.2) 8 (0.0) 392 (0.7)
Arkansas 22,091 24 (0.1) 31 (0.1) 98 (0.4) 153 (0.7)
California
Los Angeles 54,816 389 (0.7) 357 (0.7) 1 (0.0) 747 (1.4)
San Francisco 22,947 128 (0.6) 552 (2.4) 0 (0.0) 680 (3)
California (excludes Los Angeles and San Francisco) 26,836 234 (0.9) 139 (0.5) 14 (0.1) 387 (1.4)
Colorado 7,213 64 (0.9) 11 (0.2) 0 (0.0) 75 (1)
Connecticut 77,201 109 (0.1) 20 (0.0) 2 (0.0) 131 (0.2)
Delaware 4,754 15 (0.3) 12 (0.3) 1 (0.0) 28 (0.6)
District of Columbia 15,104 114 (0.8) 92 (0.6) 18 (0.1) 224 (1.5)
Florida 215,778 1,261 (0.6) 1,644 (0.8) 156 (0.1) 3,061 (1.4)
Georgia 86,171 694 (0.8) 265 (0.3) 27 (0.0) 986 (1.1)
Hawaii 1,717 10 (0.6) 2 (0.1) 0 (0.0) 12 (0.7)
Idaho 6,047 11 (0.2) 2 (0.0) 2 (0.0) 15 (0.2)
Illinois
Chicago 6,479 33 (0.5) 28 (0.4) 0 (0.0) 61 (0.9)
Illinois (excludes Chicago) 38,423 23 (0.1) 10 (0.0) 7 (0.0) 40 (0.1)
Indiana 16,635 80 (0.5) 15 (0.1) 14 (0.1) 109 (0.7)
Iowa 8,128 29 (0.4) 5 (0.1) 1 (0.0) 35 (0.4)
Kansas 14,382 40 (0.3) 12 (0.1) 1 (0.0) 53 (0.4)
Kentucky 14,291 33 (0.2) 40 (0.3) 2 (0.0) 75 (0.5)
Louisiana 91,510 245 (0.3) 681 (0.7) 12 (0.0) 938 (1)
Maine 1,117 6 (0.5) 1 (0.1) 0 (0.0) 7 (0.6)
Maryland
Baltimore 25,774 49 (0.2) 225 (0.9) 26 (0.1) 300 (1.2)
Maryland (excludes Baltimore) 21,468 26 (0.1) 30 (0.1) 1 (0.0) 57 (0.3)
Massachusetts 39,124 90 (0.2) 439 (1.1) 0 (0.0) 529 (1.4)
Michigan 22,908 149 (0.7) 56 (0.2) 17 (0.1) 222 (1)
Minnesota 3,558 10 (0.3) 10 (0.3) 4 (0.1) 24 (0.7)
Mississippi 28,214 122 (0.4) 59 (0.2) 0 (0.0) 181 (0.6)
Missouri 11,707 77 (0.7) 55 (0.5) 90 (0.8) 222 (1.9)
Montana 1,565 0 (0.0) 0 (0.0) 6 (0.4) 6 (0.4)
Nebraska 4,274 16 (0.4) 6 (0.1) 0 (0.0) 22 (0.5)
Nevada 18,633 132 (0.7) 136 (0.7) 11 (0.1) 279 (1.5)
New Hampshire 430 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
New Jersey 33,046 234 (0.7) 247 (0.7) 4 (0.0) 485 (1.5)
New Mexico 6,048 32 (0.5) 6 (0.1) 0 (0.0) 38 (0.6)
New York
New York City 35,392 154 (0.4) 200 (0.6) 43 (0.1) 397 (1.1)
New York (excludes New York City) 14,526 108 (0.7) 232 (1.6) 40 (0.3) 380 (2.6)
North Carolina 23,427 70 (0.3) 102 (0.4) 0 (0.0) 172 (0.7)
North Dakota 3,962 6 (0.2) 1 (0.0) 1 (0.0) 8 (0.2)
Ohio 7,209 145 (2) 30 (0.4) 0 (0.0) 175 (2.4)
Oklahoma 4,171 17 (0.4) 4 (0.1) 83 (2) 104 (2.5)
Oregon 7,146 33 (0.5) 24 (0.3) 1 (0.0) 58 (0.8)
Pennsylvania
Pennsylvania (excludes Philadelphia) 51,168 143 (0.3) 262 (0.5) 1 (0.0) 406 (0.8)
Philadelphia 27,424 119 (0.4) 160 (0.6) 50 (0.2) 329 (1.2)
Rhode Island 1,201 2 (0.2) 5 (0.4) 1 (0.1) 8 (0.7)
South Carolina 60,124 274 (0.5) 87 (0.1) 61 (0.1) 422 (0.7)
South Dakota 973 3 (0.3) 0 (0.0) 4 (0.4) 7 (0.7)
Tennessee 63,275 499 (0.8) 259 (0.4) 5 (0.0) 763 (1.2)
Texas
Houston 72,876 326 (0.4) 667 (0.9) 1 (0.0) 994 (1.4)
Texas (excludes Houston) 227,018 841 (0.4) 1,168 (0.5) 2 (0.0) 2,011 (0.9)
Utah 1,716 7 (0.4) 2 (0.1) 0 (0.0) 9 (0.5)
Vermont 29 0 (0.0) 0 (0.0) 1 (3.4) 1 (3.4)
Virginia 26,750 119 (0.4) 73 (0.3) 3 (0.0) 195 (0.7)
Washington 10,080 40 (0.4) 15 (0.1) 3 (0.0) 58 (0.6)
West Virginia 3,488 6 (0.2) 9 (0.3) 46 (1.3) 61 (1.7)
Wisconsin 8,429 29 (0.3) 7 (0.1) 22 (0.3) 58 (0.7)
Wyoming 3,033 1 (0.0) 0 (0.0) 4 (0.1) 5 (0.2)
Puerto Rico 13,293 150 (1.1) 75 (0.6) 1 (0.0) 226 (1.7)
U.S. Virgin Islands 1,258 15 (1.2) 9 (0.7) 0 (0.0) 24 (1.9)
Total 1,736,850 8,149 (0.5) 9,123 (0.5) 972 (0.1) 18,244 (1.1)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A positive test includes unconfirmed preliminary positive rapid tests and confirmed positive tests.
c A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.
d A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.
e A positive test that was missing information on prior HIV status or was reported as unable to determine prior HIV status (i.e., the HIV surveillance system was not checked, no other data sources were reviewed, and there is no information from the client about previous HIV test results)

Appendix Table 2. Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
Health care settings Non-health care settings
HIV testsa Newly diagnosed HIV-positive testsb HIV testsa Newly diagnosed HIV-positive testsb
CDC-funded jurisdiction No. (%) No. (%) No. (%) No. (%)
Alabama 364 (0.6) 0 (0.0) 59,886 (99.4) 323 (0.5)
Alaska 234 (54.9) 2 (0.9) 166 (39) 0 (0.0)
Arizona 54,790 (91.6) 214 (0.4) 4,048 (6.8) 23 (0.6)
Arkansas 20,744 (93.9) 0 (0.0) 1,228 (5.6) 23 (1.9)
California
Los Angeles 33,516 (61.1) 193 (0.6) 18,278 (33.3) 183 (1)
San Francisco 22,889 (99.7) 128 (0.6) 58 (0.3) 0 (0.0)
California (excludes Los Angeles and San Francisco) 17,655 (65.8) 148 (0.8) 5,547 (20.7) 39 (0.7)
Colorado 5,273 (73.1) 46 (0.9) 1,940 (26.9) 18 (0.9)
Connecticut 75,606 (97.9) 102 (0.1) 1,295 (1.7) 7 (0.5)
Delaware 3,006 (63.2) 8 (0.3) 1,424 (30) 7 (0.5)
District of Columbia 9,080 (60.1) 78 (0.9) 5,852 (38.7) 36 (0.6)
Florida 118,726 (55) 748 (0.6) 92,176 (42.7) 495 (0.5)
Georgia 53,854 (62.5) 237 (0.4) 31,675 (36.8) 456 (1.4)
Hawaii 466 (27.1) 2 (0.4) 1,197 (69.7) 8 (0.7)
Idaho 5,799 (95.9) 11 (0.2) 194 (3.2) 0 (0.0)
Illinois
Chicago 3,955 (61) 16 (0.4) 2,522 (38.9) 17 (0.7)
Illinois (excludes Chicago) 31,736 (82.6) 14 (0.0) 6,687 (17.4) 9 (0.1)
Indiana 9,804 (58.9) 46 (0.5) 6,828 (41) 34 (0.5)
Iowa 6,489 (79.8) 26 (0.4) 1,639 (20.2) 3 (0.2)
Kansas 11,026 (76.7) 20 (0.2) 3,356 (23.3) 20 (0.6)
Kentucky 11,663 (81.6) 22 (0.2) 2,628 (18.4) 11 (0.4)
Louisiana 73,469 (80.3) 164 (0.2) 17,882 (19.5) 81 (0.5)
Maine 819 (73.3) 6 (0.7) 264 (23.6) 0 (0.0)
Maryland
Baltimore 25,381 (98.5) 49 (0.2) 319 (1.2) 0 (0.0)
Maryland (excludes Baltimore) 19,011 (88.6) 22 (0.1) 2,441 (11.4) 4 (0.2)
Massachusetts 37,150 (95) 65 (0.2) 1,974 (5) 25 (1.3)
Michigan 20,170 (88) 116 (0.6) 2,307 (10.1) 32 (1.4)
Minnesota 682 (19.2) 0 (0.0) 2,865 (80.5) 10 (0.3)
Mississippi 25,891 (91.8) 114 (0.4) 2,167 (7.7) 7 (0.3)
Missouri 6,865 (58.6) 47 (0.7) 4,842 (41.4) 30 (0.6)
Montana 741 (47.3) 0 (0.0) 815 (52.1) 0 (0.0)
Nebraska 2,788 (65.2) 11 (0.4) 1,486 (34.8) 5 (0.3)
Nevada 7,731 (41.5) 46 (0.6) 10,902 (58.5) 86 (0.8)
New Hampshire 243 (56.5) 0 (0.0) 187 (43.5) 0 (0.0)
New Jersey 19,133 (57.9) 149 (0.8) 13,913 (42.1) 85 (0.6)
New Mexico 4,520 (74.7) 19 (0.4) 1,528 (25.3) 13 (0.9)
New York
New York City 32,772 (92.6) 128 (0.4) 2,088 (5.9) 25 (1.2)
New York (excludes New York City) 4,441 (30.6) 64 (1.4) 8,552 (58.9) 43 (0.5)
North Carolina 2,656 (11.3) 7 (0.3) 20,341 (86.8) 63 (0.3)
North Dakota 383 (9.7) 0 (0.0) 3,579 (90.3) 6 (0.2)
Ohio 4,518 (62.7) 101 (2.2) 2,689 (37.3) 44 (1.6)
Oklahoma 53 (1.3) 0 (0.0) 4,118 (98.7) 17 (0.4)
Oregon 5,452 (76.3) 22 (0.4) 1,660 (23.2) 11 (0.7)
Pennsylvania
Pennsylvania (excludes Philadelphia) 46,626 (91.1) 128 (0.3) 4,293 (8.4) 15 (0.3)
Philadelphia 23,253 (84.8) 102 (0.4) 3,706 (13.5) 16 (0.4)
Rhode Island 3 (0.2) 0 (0.0) 872 (72.6) 2 (0.2)
South Carolina 51,504 (85.7) 186 (0.4) 8,423 (14) 85 (1)
South Dakota 675 (69.4) 3 (0.4) 298 (30.6) 0 (0.0)
Tennessee 58,262 (92.1) 422 (0.7) 4,868 (7.7) 77 (1.6)
Texas
Houston 66,427 (91.2) 194 (0.3) 6,449 (8.8) 132 (2)
Texas (excludes Houston) 197,020 (86.8) 547 (0.3) 27,272 (12) 276 (1)
Utah 1,580 (92.1) 7 (0.4) 2 (0.1) 0 (0.0)
Vermont 2 (6.9) 0 (0.0) 27 (93.1) 0 (0.0)
Virginia 17,164 (64.2) 55 (0.3) 9,212 (34.4) 63 (0.7)
Washington 6,333 (62.8) 17 (0.3) 3,746 (37.2) 23 (0.6)
West Virginia 2,687 (77) 5 (0.2) 801 (23) 1 (0.1)
Wisconsin 3,810 (45.2) 10 (0.3) 4,619 (54.8) 19 (0.4)
Wyoming 3,033 (100) 1 (0.0) 0 (0.0) 0 (0.0)
Puerto Rico 7,648 (57.5) 134 (1.8) 5,618 (42.3) 15 (0.3)
U.S. Virgin Islands 703 (55.9) 13 (1.8) 555 (44.1) 2 (0.4)
Total 1,278,274 (73.6) 5,015 (0.4) 436,304 (25.1) 3,025 (0.7)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

Appendix Table 3. CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
HIV tests Linkage to HIV Medical Care in 30 daysc
CDC-funded jurisdiction All HIV testsa Newly diagnosed HIV-positive testsb Newly diagnosed HIV-positive tests (%) Linked Not linked Missing /invalid Missing /invalid (%) Denominator for report percentaged Reported Percentagee (%)
Alabama 60,250 323 (0.5) 227 88 8 (2.5) 315 (72.1)
Alaska 426 2 (0.5) 2 0 0 (0.0) 2 (100.0)
Arizona 59,817 238 (0.4) 204 33 1 (0.4) 237 (86.1)
Arkansas 22,091 24 (0.1) 16 5 3 (12.5) 21 (76.2)
California
Los Angeles 54,816 389 (0.7) 207 162 20 (5.1) 369 (56.1)
San Francisco 22,947 128 (0.6) 54 67 7 (5.5) 121 (44.6)
California (excludes Los Angeles and San Francisco) 26,836 234 (0.9) 180 32 22 (9.4) 212 (84.9)
Colorado 7,213 64 (0.9) 50 12 2 (3.1) 62 (80.6)
Connecticut 77,201 109 (0.1) 102 7 0 (0.0) 109 (93.6)
Delaware 4,754 15 (0.3) 13 2 0 (0.0) 15 (86.7)
District of Columbia 15,104 114 (0.8) 86 23 5 (4.4) 109 (78.9)
Florida 215,778 1,261 (0.6) 688 207 366 (29) 895 (76.9)
Georgia 86,171 694 (0.8) 505 132 57 (8.2) 637 (79.3)
Hawaii 1,717 10 (0.6) 7 2 1 (10) 9 (77.8)
Idaho 6,047 11 (0.2) 11 0 0 (0.0) 11 (100.0)
Illinois
Chicago 6,479 33 (0.5) 17 5 11 (33.3) 22 (77.3)
Illinois (excludes Chicago) 38,423 23 (0.1) 21 2 0 (0.0) 23 (91.3)
Indiana 16,635 80 (0.5) 46 25 9 (11.3) 71 (64.8)
Iowa 8,128 29 (0.4) 24 2 3 (10.3) 26 (92.3)
Kansas 14,382 40 (0.3) 31 9 0 (0.0) 40 (77.5)
Kentucky 14,291 33 (0.2) 12 16 5 (15.2) 28 (42.9)
Louisiana 91,510 245 (0.3) 191 27 27 (11) 218 (87.6)
Maine 1,117 6 (0.5) 3 3 0 (0.0) 6 (50.0)
Maryland
Baltimore 25,774 49 (0.2) 22 8 19 (38.8) 30 (73.3)
Maryland (excludes Baltimore) 21,468 26 (0.1) 6 2 18 (69.2) 8 (75.0)
Massachusetts 39,124 90 (0.2) 67 21 2 (2.2) 88 (76.1)
Michigan 22,908 149 (0.7) 115 33 1 (0.7) 148 (77.7)
Minnesota 3,558 10 (0.3) 7 1 2 (20.0) 8 (87.5)
Mississippi 28,214 122 (0.4) 77 45 0 (0.0) 122 (63.1)
Missouri 11,707 77 (0.7) 14 18 45 (58.4) 32 (43.8)
Montana 1,565 0
Nebraska 4,274 16 (0.4) 11 5 0 (0.0) 16 (68.8)
Nevada 18,633 132 (0.7) 107 8 17 (12.9) 115 (93.0)
New Hampshire 430 0
New Jersey 33,046 234 (0.7) 189 28 17 (7.3) 217 (87.1)
New Mexico 6,048 32 (0.5) 23 9 0 (0.0) 32 (71.9)
New York
New York City 35,392 154 (0.4) 117 23 14 (9.1) 140 (83.6)
New York (excludes New York City) 14,526 108 (0.7) 91 17 0 (0.0) 108 (84.3)
North Carolina 23,427 70 (0.3) 37 33 0 (0.0) 70 (52.9)
North Dakota 3,962 6 (0.2) 3 3 0 (0.0) 6 (50.0)
Ohio 7,209 145 (2) 110 31 4 (2.8) 141 (78.0)
Oklahoma 4,171 17 (0.4) 16 0 1 (5.9) 16 (100.0)
Oregon 7,146 33 (0.5) 16 16 1 (3.0) 32 (50.0)
Pennsylvania
Pennsylvania (excludes Philadelphia) 51,168 143 (0.3) 116 27 0 (0.0) 143 (81.1)
Philadelphia 27,424 119 (0.4) 99 19 1 (0.8) 118 (83.9)
Rhode Island 1,201 2 (0.2) 1 1 0 (0.0) 2 (50.0)
South Carolina 60,124 274 (0.5) 146 45 83 (30.3) 191 (76.4)
South Dakota 973 3 (0.3) 2 1 0 (0.0) 3 (66.7)
Tennessee 63,275 499 (0.8) 163 18 318 (63.7) 181 (90.1)
Texas
Houston 72,876 326 (0.4) 188 35 103 (31.6) 223 (84.3)
Texas (excludes Houston) 227,018 841 (0.4) 643 170 28 (3.3) 813 (79.1)
Utah 1,716 7 (0.4) 3 4 0 (0.0) 7 (42.9)
Vermont 29 0
Virginia 26,750 119 (0.4) 94 21 4 (3.4) 115 (81.7)
Washington 10,080 40 (0.4) 26 11 3 (7.5) 37 (70.3)
West Virginia 3,488 6 (0.2) 4 0 2 (33.3) 4 (100)
Wisconsin 8,429 29 (0.3) 22 6 1 (3.4) 28 (78.6)
Wyoming 3,033 1 (0.0) 0 0 1 (100.0) 0
Puerto Rico 13,293 150 (1.1) 129 20 1 (0.7) 149 (86.6)
U.S. Virgin Islands 1,258 15 (1.2) 6 6 3 (20) 12 (50.0)
Total 1,736,850 8,149 (0.5) 5,367 1,546 1,236 (15.2) 6,913 (77.6)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.
c A newly diagnosed person is considered linked to HIV medical care within 30 days if they attended an appointment for HIV medical care within 30 days after diagnosis.
d Number of persons with newly diagnosed HIV infection whose test records have valid and complete information on attendance and on date of first appointment for HIV medical care within 30 days after diagnosis. This is the denominator used to calculate the reported percentage.
e Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or “Don’t Know”).

Appendix Table 4: CDC-funded HIV testing and linkage to HIV medical care among persons with newly diagnosed HIV infection by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
HIV tests Linkage to HIV medical care in 30 daysc
Characteristics All testsa Percent of all tests (%) Newly diagnosed HIV-positive testsb Newly diagnosed HIV-positive tests (%) Linked Not linked Missing /invalid Missing /invalid (%) Denominator for report percentaged Reported Percentagee (%)
Age at test (years)
<13 2,910 (0.2) 2 (0.1) 1 0 1 (50.0) 1 (100.0)
13-19 88,767 (5.1) 206 (0.2) 148 34 24 (11.7) 182 (81.3)
20-29 583,150 (33.6) 3,253 (0.6) 2,263 587 403 (12.4) 2,850 (79.4)
30-39 466,054 (26.8) 2,576 (0.6) 1,724 516 336 (13.0) 2,240 (77.0)
40-49 257,568 (14.8) 1,072 (0.4) 663 223 186 (17.4) 886 (74.8)
50+ 317,968 (18.3) 876 (0.3) 541 183 152 (17.4) 724 (74.7)
Missing/invalid 20,433 (1.2) 164 (0.8) 27 3 134 (81.7) 30 (90.0)
Gender
Men 913,661 (52.6) 6,864 (0.8) 4,571 1,294 999 (14.6) 5,865 (77.9)
Women 798,644 (46.0) 1,029 (0.1) 628 191 210 (20.4) 819 (76.7)
Transgender 16,225 (0.9) 231 (1.4) 153 51 27 (11.7) 204 (75.0)
Another gender 4,263 (0.2) 16 (0.4) 9 7 0 0.0 16 (56.3)
Declined/not asked/unknown/missing 4,057 (0.2) 9 (0.2) 6 3 0 0.0 9 (66.7)
Race/Ethnicity
American Indian or Alaska Native 10,145 (0.6) 38 (0.4) 25 10 3 (7.9) 35 (71.4)
Asian 42,175 (2.4) 154 (0.4) 105 30 19 (12.3) 135 (77.8)
Black or African American 654,965 (37.7) 3,621 (0.6) 2,265 699 657 (18.1) 2,964 (76.4)
Hispanic or Latino 450,209 (25.9) 2,509 (0.6) 1,850 395 264 (10.5) 2,245 (82.4)
Native Hawaiian or Pacific Islander 3,878 (0.2) 17 (0.4) 11 6 0 0.0 17 (64.7)
White 479,511 (27.6) 1,599 (0.3) 987 366 246 (15.4) 1,353 (72.9)
Two or more races selected 14,170 (0.8) 80 (0.6) 52 16 12 (15.0) 68 (76.5)
Declined 30,954 (1.8) 47 (0.2) 29 12 6 (12.8) 41 (70.7)
Don’t know/not asked 31,904 (1.8) 64 (0.2) 37 9 18 (28.1) 46 (80.4)
Missing/invalid 18,939 (1.1) 20 (0.1) 6 3 11 (55.0) 9 (66.7)
Population groups in non-health care facilitiesf
Men who have sex with men and who inject drugs 4,830 (1.1) 136 (2.8) 86 36 14 (10.3) 122 (70.5)
Men who have sex with men 96,643 (22.2) 1,873 (1.9) 1,367 309 197 (10.5) 1,676 (81.6)
Transgender persons who inject drugs 754 (0.2) 17 (2.3) 9 5 3 (17.6) 14 (64.3)
Transgender persons 6,280 (1.4) 89 (1.4) 57 19 13 (14.6) 76 (75.0)
Persons who inject drugs 27,866 (6.4) 101 (0.4) 56 31 14 (13.9) 87 (64.4)
Heterosexual men 114,364 (26.2) 389 (0.3) 236 96 57 (14.7) 332 (71.1)
Heterosexual women 128,567 (29.5) 235 (0.2) 158 38 39 (16.6) 196 (80.6)
Women who have sex with women 9,193 (2.1) 20 (0.2) 8 11 1 (5.0) 19 (42.1)
Sex with transgender persons 778 (0.2) 9 (1.2) 9 0 0 0.0 9 (100.0)
No sexual contact or injection drug use 23,241 (5.3) 123 (0.5) 64 38 21 (17.1) 102 (62.7)
Missing/invalid 23,788 (5.5) 33 (0.1) 19 10 4 (12.1) 29 (65.5)
Region
Northeast 280,658 (16.2) 965 (0.3) 785 146 34 (3.5) 931 (84.3)
Midwest 147,067 (8.5) 640 (0.4) 423 141 76 (11.9) 564 (75.0)
South 1,066,534 (61.4) 5,058 (0.5) 3,134 877 1,047 (20.7) 4,011 (78.1)
West 228,040 (13.1) 1,321 (0.6) 890 356 75 (5.7) 1,246 (71.4)
U.S. dependent areas 14,551 (0.8) 165 (1.1) 135 26 4 (2.4) 161 (83.9)
Testing site type
Health care facilities 1,278,274 (73.6) 5,015 (0.4) 3,232 926 857 (17.1) 4,158 (77.7)
Non-health care facilities 436,304 (25.1) 3,025 (0.7) 2,069 593 363 (12.0) 2,662 (77.7)
Mobile units 16,743 (1) 87 (0.5) 52 24 11 (12.6) 76 (68.4)
Self-testing 3,990 (0.2) 9 (0.2) 6 2 1 (11.1) 8 (75.0)
Unknown 1,539 (0.1) 13 (0.8) 8 1 4 (30.8) 9 (88.9)
Total 1,736,850 (100.0) 8,149 (0.5) 5,367 1,546 1,236 (15.2) 6,913 (77.6)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.
c A newly diagnosed person is considered linked to HIV medical care within 30 days if they attended an appointment for HIV medical care within 30 days after diagnosis.
d Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and on date of first appointment for HIV medical care within 30 days after diagnosis. This is the denominator used to calculate the reported percentage.
e Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or “Don’t Know”).
f Data on behaviors that define population groups are collected for all tests performed in non-healthcare settings and for HIV-positive tests in health care settings. Groups are mutually exclusive and based on behaviors reported in the past 12 months under the old (prior to 2018) NHM&E reporting requirements and in the past 5 years under the new NHM&E requirements.

Appendix Table 5. CDC-funded HIV testing and interview for partner services among persons with newly diagnosed HIV infection, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
HIV tests Interviewed for partner services
CDC-funded jurisdiction All HIV testsa Newly diagnosed HIV-positive testsb Newly diagnosed HIV positivity (%) Interviewed Not Interviewed Missing /invalid Missing /invalid (%) Denominator for reported percentagec Reported percentaged (%)
Alabama 60,250 323 (0.5) 221 98 4 (1.2) 319 (69.3)
Alaska 426 2 (0.5) 2 0 0 0.0 2 (100.0)
Arizona 59,817 238 (0.4) 196 25 17 (7.1) 221 (88.7)
Arkansas 22,091 24 (0.1) 20 3 1 (4.2) 23 (87.0)
California
Los Angeles 54,816 389 (0.7) 7 20 362 (93.1) 27 (25.9)
San Francisco 22,947 128 (0.6) 72 56 0 0.0 128 (56.3)
California (excludes Los Angeles and San Francisco) 26,836 234 (0.9) 100 59 75 (32.1) 159 (62.9)
Colorado 7,213 64 (0.9) 60 2 2 (3.1) 62 (96.8)
Connecticut 77,201 109 (0.1) 107 2 0 0.0 109 (98.2)
Delaware 4,754 15 (0.3) 13 2 0 0.0 15 (86.7)
District of Columbia 15,104 114 (0.8) 33 60 21 (18.4) 93 (35.5)
Florida 215,778 1,261 (0.6) 670 32 559 (44.3) 702 (95.4)
Georgia 86,171 694 (0.8) 164 141 389 (56.1) 305 (53.8)
Hawaii 1,717 10 (0.6) 10 0 0 0.0 10 (100.0)
Idaho 6,047 11 (0.2) 11 0 0 0.0 11 (100.0)
Illinois
Chicago 6,479 33 (0.5) 8 3 22 (66.7) 11 (72.7)
Illinois (excludes Chicago) 38,423 23 (0.1) 23 0 0 0.0 23 (100.0)
Indiana 16,635 80 (0.5) 43 24 13 (16.3) 67 (64.2)
Iowa 8,128 29 (0.4) 24 5 0 0.0 29 (82.8)
Kansas 14,382 40 (0.3) 38 2 0 0.0 40 (95.0)
Kentucky 14,291 33 (0.2) 27 3 3 (9.1) 30 (90.0)
Louisiana 91,510 245 (0.3) 136 0 109 (44.5) 136 (100.0)
Maine 1,117 6 (0.5) 5 1 0 0.0 6 (83.3)
Maryland
Baltimore 25,774 49 (0.2) 37 7 5 (10.2) 44 (84.1)
Maryland (excludes Baltimore) 21,468 26 (0.1) 5 18 3 (11.5) 23 (21.7)
Massachusetts 39,124 90 (0.2) 48 34 8 (8.9) 82 (58.5)
Michigan 22,908 149 (0.7) 104 39 6 (4.0) 143 (72.7)
Minnesota 3,558 10 (0.3) 2 4 4 (40.0) 6 (33.3)
Mississippi 28,214 122 (0.4) 102 9 11 (9.0) 111 (91.9)
Missouri 11,707 77 (0.7) 59 5 13 (16.9) 64 (92.2)
Montana 1,565 0
Nebraska 4,274 16 (0.4) 10 6 0 0.0 16 (62.5)
Nevada 18,633 132 (0.7) 112 12 8 (6.1) 124 (90.3)
New Hampshire 430 0
New Jersey 33,046 234 (0.7) 152 55 27 (11.5) 207 (73.4)
New Mexico 6,048 32 (0.5) 24 8 0 0.0 32 (75.0)
New York
New York City 35,392 154 (0.4) 78 52 24 (15.6) 130 (60.0)
New York (excludes New York City) 14,526 108 (0.7) 39 9 60 (55.6) 48 (81.3)
North Carolina 23,427 70 (0.3) 53 14 3 (4.3) 67 (79.1)
North Dakota 3,962 6 (0.2) 6 0 0 0.0 6 (100.0)
Ohio 7,209 145 (2.0) 101 31 13 (9.0) 132 (76.5)
Oklahoma 4,171 17 (0.4) 0 0 17 (100.0) 0
Oregon 7,146 33 (0.5) 28 3 2 (6.1) 31 (90.3)
Pennsylvania
Pennsylvania (excludes Philadelphia) 51,168 143 (0.3) 131 12 0 0.0 143 (91.6)
Philadelphia 27,424 119 (0.4) 38 56 25 (21.0) 94 (40.4)
Rhode Island 1,201 2 (0.2) 2 0 0 0.0 2 (100.0)
South Carolina 60,124 274 (0.5) 105 57 112 (40.9) 162 (64.8)
South Dakota 973 3 (0.3) 3 0 0 0.0 3 (100.0)
Tennessee 63,275 499 (0.8) 132 6 361 (72.3) 138 (95.7)
Texas
Houston 72,876 326 (0.4) 4 1 321 (98.5) 5 (80.0)
Texas (excludes Houston) 227,018 841 (0.4) 400 363 78 (9.3) 763 (52.4)
Utah 1,716 7 (0.4) 6 1 0 0.0 7 (85.7)
Vermont 29 0
Virginia 26,750 119 (0.4) 99 7 13 (10.9) 106 (93.4)
Washington 10,080 40 (0.4) 26 10 4 (10.0) 36 (72.2)
West Virginia 3,488 6 (0.2) 1 0 5 (83.3) 1 (100.0)
Wisconsin 8,429 29 (0.3) 20 8 1 (3.4) 28 (71.4)
Wyoming 3,033 1 0.0 1 0 0 0.0 1 (100.0)
Puerto Rico 13,293 150 (1.1) 123 17 10 (6.7) 140 (87.9)
U.S. Virgin Islands 1,258 15 (1.2) 10 3 2 (13.3) 13 (76.9)
Total 1,736,850 8,149 (0.5) 4,051 1,385 2,713 (33.3) 5,436 (74.5)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.
c Number of persons with newly diagnosed HIV infection whose test records have valid and complete information on interview for Partner Services. This is the denominator used to calculate the reported percentage.
d Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or “Don’t Know”).

Appendix Table 6. CDC-funded HIV testing and linkage to HIV medical care among persons with previously diagnosed HIV infection not in HIV medical care, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2021
HIV tests Linkage to HIV Medical Care in 30 daysd
CDC-funded jurisdiction All HIV testsa Previously diagnosed HIV-positive testsb Previously diagnosed HIV-positive tests not in carec Linked Not linked Missing /invalid Missing /invalid (%) Denominator for report percentagee Reported Percentagef (%)
Alabama 60,250 397 220 46 167 7 (3.2) 213 (21.6)
Alaska 426 1 0 0 0 0 0
Arizona 59,817 146 67 37 29 1 (1.5) 66 (56.1)
Arkansas 22,091 31 6 0 6 0 0.0 6 0.0
California
Los Angeles 54,816 357 104 63 27 14 (13.5) 90 (70.0)
San Francisco 22,947 552 118 17 100 1 (0.8) 117 (14.5)
California (excludes Los Angeles and San Francisco) 26,836 139 64 51 7 6 (9.4) 58 (87.9)
Colorado 7,213 11 2 1 1 0 0.0 2 (50.0)
Connecticut 77,201 20 16 13 3 0 0.0 16 (81.3)
Delaware 4,754 12 6 3 3 0 0.0 6 (50.0)
District of Columbia 15,104 92 12 5 6 1 (8.3) 11 (45.5)
Florida 215,778 1,644 14 10 1 3 (21.4) 11 (90.9)
Georgia 86,171 265 204 132 43 29 (14.2) 175 (75.4)
Hawaii 1,717 2 0 0 0 0 0
Idaho 6,047 2 0 0 0 0 0
Illinois
Chicago 6,479 28 6 2 3 1 (16.7) 5 (40.0)
Illinois (excludes Chicago) 38,423 10 2 2 0 0 0.0 2 (100.0)
Indiana 16,635 15 2 0 1 1 (50.0) 1 0.0
Iowa 8,128 5 0 0 0 0 0
Kansas 14,382 12 0 0 0 0 0
Kentucky 14,291 40 13 7 5 1 (7.7) 12 (58.3)
Louisiana 91,510 681 5 5 0 0 0.0 5 (100.0)
Maine 1,117 1 1 0 1 0 0.0 1 0.0
Maryland
Baltimore 25,774 225 0 0 0 0 0
Maryland (excludes Baltimore) 21,468 30 9 4 1 4 (44.4) 5 (80.0)
Massachusetts 39,124 439 263 112 145 6 (2.3) 257 (43.6)
Michigan 22,908 56 21 11 10 0 0.0 21 (52.4)
Minnesota 3,558 10 0 0 0 0 0
Mississippi 28,214 59 4 4 0 0 0.0 4 (100.0)
Missouri 11,707 55 2 1 0 1 (50.0) 1 (100.0)
Montana 1,565 0
Nebraska 4,274 6 0 0 0 0 0
Nevada 18,633 136 31 23 7 1 (3.2) 30 (76.7)
New Hampshire 430 0
New Jersey 33,046 247 80 62 15 3 (3.8) 77 (80.5)
New Mexico 6,048 6 4 1 3 0 0.0 4 (25.0)
New York
New York City 35,392 200 111 94 9 8 (7.2) 103 (91.3)
New York (excludes New York City) 14,526 232 30 27 3 0 0.0 30 (90.0)
North Carolina 23,427 102 30 10 20 0 0.0 30 (33.3)
North Dakota 3,962 1 1 1 0 0 0.0 1 (100.0)
Ohio 7,209 30 18 16 1 1 (5.6) 17 (94.1)
Oklahoma 4,171 4 4 4 0 0 0.0 4 (100.0)
Oregon 7,146 24 5 2 3 0 0.0 5 (40.0)
Pennsylvania
Pennsylvania (excludes Philadelphia) 51,168 262 112 34 78 0 0.0 112 (30.4)
Philadelphia 27,424 160 69 43 26 0 0.0 69 (62.3)
Rhode Island 1,201 5 1 0 1 0 0.0 1 0.0
South Carolina 60,124 87 34 24 10 0 0.0 34 (70.6)
South Dakota 973 0
Tennessee 63,275 259 52 24 19 9 (17.3) 43 (55.8)
Texas
Houston 72,876 667 192 56 26 110 (57.3) 82 (68.3)
Texas (excludes Houston) 227,018 1,168 259 145 113 1 (0.4) 258 (56.2)
Utah 1,716 2 0 0 0 0 0
Vermont 29 0
Virginia 26,750 73 16 10 5 1 (6.3) 15 (66.7)
Washington 10,080 15 5 4 1 0 0.0 5 (80.0)
West Virginia 3,488 9 1 0 0 1 (100.0) 0
Wisconsin 8,429 7 5 5 0 0 0.0 5 (100.0)
Wyoming 3,033 0
Puerto Rico 13,293 75 26 23 2 1 (3.8) 25 (92.0)
U.S. Virgin Islands 1,258 9 3 3 0 0 0.0 3 (100.0)
Total 1,736,850 9,123 2,250 1,137 901 212 (9.4) 2,038 (55.8)

Data Source: National HIV Prevention Program Monitoring and Evaluation data reported through EvaluationWeb® as of September 15, 2022.
a Total number of tests includes tests with negative or positive results; tests with discordant or inconclusive results are excluded.
b A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV tests or evidence of a previous positive tests found on review of other data sources.
c Excludes persons already in HIV medical care.
d A previously diagnosed person is considered linked to HIV medical care within 30 days if they attended an appointment for HIV medical care within 30 days after the current positive HIV test.
e Number of persons with previously diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days after the current HIV positive test. This is the denominator used to calculate the reported percentage.
f Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or “Don’t Know”).